DIABETIC RETINOPATHY

This page is intentionally left blank

DIABETIC RETINOPATHY

José Cunha-Vaz

University of Coimbra, Portugal

NEW JERSEY • LONDON • SINGAPORE • BEIJING • SHANGHAI • HONG KONG • TAIPEI • CHENNAI

Published by

World Scientific Publishing Co. Pte. Ltd.

5 Toh Tuck Link, Singapore 596224

USA office: 27 Warren Street, Suite 401-402, Hackensack, NJ 07601

UK office: 57 Shelton Street, Covent Garden, London WC2H 9HE

Library of Congress Cataloging-in-Publication Data

Diabetic retinopathy / [edited by] José Cunha-Vaz.

p. ; cm.

Includes bibliographical references and index.

ISBN-13: 978-981-4304-43-6 (hardcover : alk. paper)

ISBN-10: 981-4304-43-3 (hardcover : alk. paper)

1. Diabetic retinopathy. I. Cunha-Vaz, José G.

[DNLM: 1. Diabetic Retinopathy. WK 835]

RE661.D5D523 2010

617.7'35--dc22

2010043318

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Copyright © 2011 by World Scientific Publishing Co. Pte. Ltd.

All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the Publisher.

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

Typeset by Stallion Press

Email: enquiries@stallionpress.com

Printed in Singapore.

*To my wife
Teresa Maria*

This page is intentionally left blank

Preface

Diabetic retinopathy remains the leading cause of low vision and blindness in people of working age in Europe and USA. At the same time that there has been continuous improvement in the management and treatment of diabetic retinal disease. Projections for the next decade indicate that number of persons with diabetes will increase over the next twenty to thirty years by 35% creating a real challenge to the public health capacity to care for patients with diabetic retinopathy and persons at risk for this complication.

For over forty years I have been particularly involved in the study of diabetic retinopathy. Since my earlier training days under the guidance of Norman Ashton, in London, I have always been focusing on the “whys” and “hows” of diabetic retinopathy. The goal was always to improve our understanding of its development and progression. Since London I worked for extended periods of time in Coimbra, Portugal and in Chicago, USA, at the University of Illinois Eye and Ear Infirmary. Translational research by combining laboratory with clinical research has been my main interest and a great source of personal enjoyment. This, I believe is clearly reflected in this book. For the same reasons it deals primarily with nonproliferative retinopathy in diabetes type 2, the most frequent form of diabetic retinal disease and the disease stage where the

mechanisms of the retinal pathology can be more clearly correlated with the systemic disease.

I believe strongly that improved understanding of diabetes in general is fundamental for the management of retinal disease and that an open and permanent communication between the ophthalmologist and the diabetologist is crucial for the best care to our patients with diabetic retinopathy. This is why the first chapter book includes the approved guidelines for management of diabetes and its complications.

This book is the result of a challenge by a colleague of mine, Manuel Sanchez Salorio, of Santiago de Compostela, Spain.

I hope sincerely that it may contribute by offering a balance between original thought and proven clinical practice. It would give me great pleasure if the readers, particularly young ones, find in this book concepts that stir in theirs minds new perspectives for improved understanding and management of diabetic retinopathy. This means that our patients will have better options and that their sight will have more chances to be preserved in spite of their diabetes.

Finally, I would like to thank all the authors that contributed to this book.

My personal thanks go also to the persons who helped me review and check all the details involved in the preparation of the book, namely, Alda Gonçalves, Cristina Ramos and Catarina Neves.

This page is intentionally left blank

Contents

<i>Preface</i>	v
<i>List of Contributors</i>	xix
Chapter 1 Standards of Medical Care in Diabetes — 2009 <i>American Diabetes Association</i>	1
1.1. Classification and Diagnosis	1
1.1.1. Classification	1
1.1.2. Diagnosis of Diabetes	2
1.1.3. Diagnosis of Prediabetes	3
1.2. Testing for Prediabetes and Diabetes in Asymptomatic Patients	3
1.2.1. Testing for Prediabetes and Type 2 Diabetes in Adults	4
1.2.2. Testing for Type 2 Diabetes in Children	5
1.2.3. Screening for Type 1 Diabetes	5
1.3. Detection and Diagnosis of GDM	5
1.4. Prevention/Delay of Type 2 Diabetes	7
1.5. Diabetes Care	9
1.5.1. Initial Evaluation	9
1.5.2. Management	9
1.5.3. Glycemic Control	9
1.5.3.1. Assessment of glycemic control	9
1.5.3.2. Glycemic goals in adults	13
1.6. Prevention and Management of Diabetes Complications	18
1.6.1. CVD	18
1.6.1.1. Hypertension/blood pressure control	18
1.6.1.2. Dyslipidemia/lipid management	21
1.6.1.3. Antiplatelet agents	24
1.6.1.4. Smoking cessation	25
1.6.2. Retinopathy Screening and Treatment	25
References	27

Chapter 2	Clinical Presentation of Retinopathy	37
	<i>José Cunha-Vaz</i>	
2.1.	Preclinical Stage	38
2.2.	Nonproliferative Diabetic Retinopathy	40
2.3.	Complications of Diabetic Retinal Disease	42
2.3.1.	Diabetic Macular Edema	42
2.3.2.	Preproliferative and Proliferative Diabetic Retinopathy	46
	References	49
Chapter 3	Clinical Diagnostic Methodologies	51
3.1.	Fundus Photography and Fluorescein Angiography	51
	<i>Lilianne Duarte and José Cunha-Vaz</i>	
3.1.1.	Mild Nonproliferative Retinopathy	54
3.1.2.	Moderate Nonproliferative Retinopathy Without Macular Edema	55
3.1.3.	Nonproliferative Retinopathy with Clinically Significant Macular Edema	55
3.1.4.	Severe Nonproliferative Retinopathy	56
3.1.5.	Diabetic Retinopathy Screening	56
3.1.6.	Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs-an Extension of the Modified Airlie House Classification. ETDRS Report Number 10	57
	References	60
3.2.	Measurements of Retinal Thickness	61
	<i>João Figueira, Rui Bernardes and José Cunha-Vaz</i>	
3.2.1.	Retinal Thickness Analyzer (RTA)	62
3.2.2.	Optical Coherence Tomography (OCT)	62
3.2.3.	Retinal Thickness Measurements	63
3.2.4.	Macular Edema	65
	References	68
3.3.	Vitreous Fluorometry and Retinal Leakage Measurements	69
	<i>José Cunha-Vaz and Conceição Lobo</i>	
3.3.1.	Basic Principles of Ocular Fluorometry	70
3.3.1.1.	Quantitative Measurement of Fluorescein	70
3.3.1.2.	Instrumentation and Measurement	71
3.3.1.3.	Evaluation of Blood-retinal Barrier Permeability	71
3.3.2.	Retinal Leakage Analyzer	72
3.3.3.	Experimental Studies	73
3.3.4.	Clinical Studies	74
3.3.5.	Prognostic Value of Leakage Measurements	75
	References	76
3.4.	Blood Flow	77
	<i>José Cunha-Vaz</i>	
3.4.1.	General Hemodynamic Principles	77

	3.4.2. Pressure-Volume Relationships	78
	3.4.3. Retinal Blood Volume	78
	3.4.4. Pressure-Flow Relationships	78
	3.4.5. Biophysical Factors Affecting Retinal Capillary Flow	78
	3.4.6. Velocity and Intermittence of Retinal Capillary Flow	79
	3.4.7. Regulation of Retinal Capillary Blood Flow	79
	3.4.8. Autoregulation of Retinal Blood Flow	80
	3.4.9. Measurement of Blood Flow	81
	3.4.10. Retinal Blood Flow in Diabetes	81
	References	82
	3.5. Retinal Neural Impairment	83
	<i>Miguel Castelo-Branco</i>	
	3.5.1. New Psychophysical Techniques to Assess Retinal Neural Impairment in Diabetic Retinopathy	84
	3.5.2. Classical Electrophysiological Findings in Diabetic Retinopathy	86
	3.5.3. Oscillatory Potentials (OPs)	90
	3.5.4. Pattern ERG	91
	3.5.5. Multifocal Electrophysiology	91
	3.5.6. Future Directions	92
	References	93
	Abbreviations	95
	3.6. Multimodal Macula Mapping	95
	<i>Rui Bernardes, Conceição Lobo and José Cunha-Vaz</i>	
	3.6.1. Imaging Systems	96
	3.6.2. Multimodal Macula Mapping. Integration of Information and Representation	96
	3.6.3. Multimodal Macula Mapping	96
	3.6.4. Contribution to the Evaluation of Diabetic Retinopathy	98
	References	100
Chapter 4	Pathogenesis	101
	4.1. Molecular Mechanisms	101
	<i>Paulo Pereira</i>	
	4.1.1. Glucose Transport in the Retina	102
	4.1.2. Aldose Reductase and Polyol Pathway	105
	4.1.3. Protein Glycation	106
	4.1.4. VEGF and Angiogenesis	107
	4.1.5. Activation of Protein Kinase C	109
	4.1.6. Oxidative Stress	111
	4.1.7. Hyperglycemia and Oxidative Damage: A Unifying Hypothesis	112
	4.1.8. Hyperglycemia and Production of Superoxide	113
	4.1.9. Activation of Hexosamine Pathway	114
	4.1.10. Activation of PKC	115

4.1.11.	Formation of AGEs	115
4.1.12.	Production of Nitric Oxide	115
4.1.13.	Animal Models	116
4.1.14.	Genetic Factors	116
References		117
4.2.	Cell Factors	125
	<i>António Francisco Ambrósio</i>	
4.2.1.	Cell Changes Relevant to Blood-Retinal Barrier Breakdown	126
4.2.2.	Tight Junctions	126
4.2.3.	Alterations in Tight Junctions Expression and Phosphorylation	126
4.2.4.	Microvascular Cell Death	128
4.2.5.	Neuronal Dysfunction and Death	129
4.2.6.	Glial Cells Reactivity and Changes	131
4.2.7.	Glutamate Excitotoxicity in Diabetic Retinopathy: Involvement of Neurons and Glial Cells	132
4.2.8.	Microglia	134
4.2.9.	The Outsiders: Leukocytes and Platelets	134
4.2.10.	Low-Grade Chronic Inflammation	134
4.2.11.	Microthrombosis	136
4.2.12.	Concluding Remarks	136
References		137
4.3.	Neovascularization in Diabetic Retinopathy	143
	<i>Ermelindo Leal and António Francisco Ambrósio</i>	
4.3.1.	Ischemia and Neovascularization in Diabetic Retinopathy	143
4.3.2.	Growth Factors	143
4.3.3.	Basic Fibroblast Growth Factor (bFGF)	144
4.3.4.	Insulin-Like Growth Factors (IGF)	144
4.3.5.	Platelet-Derived Growth Factor (PDGF)	145
4.3.6.	Vascular Endothelial Growth Factor (VEGF)	146
4.3.7.	Conclusions	147
References		148
4.4.	Candidate Genes of Diabetic Retinopathy	152
	<i>Alda Ambrósio</i>	
4.4.1.	Molecular Genetics Approaches to Gene Mapping in Complex Human Disease	152
4.4.2.	Genetic Susceptibility in Diabetic Retinopathy	153
4.4.3.	Candidate Genes in Diabetic Retinopathy	154
4.4.4.	Aldose Reductase Gene	155
4.4.5.	VEGF Gene	155
4.4.6.	RAGE Gene	156
4.4.7.	Angiotensin-Converting Enzyme Gene	156
4.4.8.	PAI-1 Gene	157
4.4.9.	Endothelin Genes	157

	4.4.10. Nitric Oxide Synthase Genes	158
	4.4.11. Other Candidate Genes	158
	4.4.12. Concluding Remarks	158
	References	159
Chapter 5	Epidemiology	165
	<i>José Rui Faria Abreu</i>	
5.1.	Prevalence of Visual Impairment	165
5.1.1.	Prevalence of Visual Impairment in Diabetic Patients	168
5.1.2.	Prevalence of Blindness in Diabetic Patients	168
5.2.	Incidence of Visual Impairment	169
5.2.1.	Visual Impairment	170
5.2.1.1.	Type 1 diabetes	170
5.2.1.2.	Type 2 diabetes	171
5.2.2.	Blindness	171
5.2.2.1.	Type 1 diabetes	171
5.2.2.2.	Type 2 diabetes	171
5.3.	Risk Factors for Visual Loss	172
5.3.1.	Sex	172
5.3.2.	Race	172
5.3.3.	Age	172
5.3.4.	Duration of Diabetes	172
5.3.5.	Severity of Retinopathy	172
5.3.6.	Macular Edema	173
5.3.7.	Metabolic Control	173
5.3.8.	Hypertension	174
5.3.9.	Nephropathy	174
5.4.	Economic Costs of Visual Impairment and Blindness	174
5.5.	Prevalence of Retinopathy	175
5.5.1.	Type 1 Diabetes	175
5.5.2.	Type 2 Diabetes	175
5.6.	Risk Factors of Retinopathy	177
5.6.1.	Type 1 Diabetes	177
5.6.1.1.	Duration of diabetes	177
5.6.1.2.	Age at diagnosis	178
5.6.1.3.	Glycemic control	178
5.6.1.4.	Blood pressure control	179
5.6.1.5.	Pregnancy	179
5.6.1.6.	Height, weight and body mass index (BMI)	180
5.6.1.7.	Serum lipid levels	180
5.6.1.8.	Proteinuria	180
5.6.1.9.	Cigarette smoking	180
5.6.1.10.	Alcohol	181
5.6.1.11.	Physical activity	181
5.6.1.12.	Myopia	181

5.6.2.	Type 2 Diabetes	181
5.6.2.1.	Duration of diabetes	181
5.6.2.2.	Age at examination	181
5.6.2.3.	Treatment	182
5.6.2.4.	Glycemic control	182
5.6.2.5.	Blood pressure	183
5.6.2.6.	Cholesterol and triglycerides	183
5.6.2.7.	Renal involvement	183
5.6.2.8.	Body mass index (BMI)	183
5.6.2.9.	Cigarette smoking and alcohol	184
5.6.2.10.	Physical activity	184
5.6.2.11.	Cataract extraction	184
5.7.	Retinopathy, Comorbidity and Mortality	184
5.7.1.	Comorbidity	184
5.7.2.	Mortality	185
5.8.	Health Care Delivery	185
5.8.1.	Economy	187
5.8.1.1.	Identification of costs of screening and treatment	187
5.8.1.2.	Quality of life	188
5.8.1.3.	Health care economic analyses	189
5.8.1.4.	Cost-effectiveness in diabetic retinopathy	189
	References	190
Chapter 6	Major Clinical Trials on Treatment for Diabetic Retinopathy	201
	<i>Luisa Ribeiro</i>	
	Clinical Trials	201
6.1.	Photocoagulation	202
6.1.1.	Diabetic Retinopathy Study (DRS)	202
6.1.2.	Early Treatment Diabetic Retinopathy Study (ETDRS)	203
6.2.	Vitrectomy	204
6.2.1.	Diabetic Retinopathy Vitrectomy Study (DRVS)	205
6.3.	Medical Approaches	206
6.3.1	Diabetes Control and Complications Trial (DCCT)	206
6.3.2	United Kingdom Prospective Diabetes Study (UKPDS)	207
	References	207
Chapter 7	Photocoagulation for Macular Edema and Proliferative Retinopathy	211
	<i>Francisco Gómez-Ulla</i>	
7.1.	Rationale and Results of Photocoagulation	211
7.1.1.	Diabetic Macular Edema: Results	213
7.1.2.	Proliferative Diabetic Retinopathy: Results	214
7.2.	Clinical Evaluation and Pre-treatment Options	214

	7.2.1. Macular Edema	214
	7.2.2. Proliferative Diabetic Retinopathy	217
7.3.	Laser Treatment Techniques	218
	7.3.1. Macular Edema	218
	7.3.2. Proliferative Retinopathy	222
7.4.	Post-operative Follow-up and Complications	224
	7.4.1. Macular Edema	224
	7.4.2. Proliferative Retinopathy	225
7.5.	Special Cases	227
	7.5.1. Proliferative Retinopathy and Macular Edema	227
	7.5.2. Macular Edema and Traction	228
	7.5.3. Diabetic Retinopathy and Cataract Surgery	228
	7.5.4. Proliferative Retinopathy and Traction on Vitreous Hemorrhage	229
7.6.	Conclusions and General Guidelines	230
	References	231
Chapter 8	Vitrectomy for Diabetic Retinopathy	237
	<i>José Carlos Pastor</i>	
8.1.	Surgical Indications	237
	8.1.1. Clearing Media Opacities	237
	8.1.1.1. Non-clearing vitreous hemorrhage	237
	8.1.1.2. Dense premacular hemorrhages	238
	8.1.1.3. Dense asteroid hyalosis	238
	8.1.2. Tractional Complications	238
	8.1.2.1. Tractional retinal detachment and tractional macular detachment	239
	8.1.2.2. Combined tractional and rhegmatogenous retinal detachment	240
	8.1.2.3. Severe equatorial fibrovascular proliferation	240
	8.1.2.4. Anterior hyaloidal fibrovascular proliferation	240
	8.1.3. Other Indications	241
	8.1.3.1. Severe neovascular proliferation	241
	8.1.3.2. Red blood cell-induced glaucomas	241
	8.1.3.3. Macular edema	241
	8.1.3.4. Complications of previous vitrectomies	242
8.2.	Managing Vitrectomy-Associated Cataracts	243
8.3.	Surgical Objectives and Techniques	244
	8.3.1. Media Opacities	244
	8.3.2. Vitreoretinal Traction	244
	8.3.2.1. Techniques	244
	8.3.3. Control of Hemorrhage and Vascular Proliferation	245
	8.3.3.1. Hemorrhage	245
	8.3.3.2. Vascular Proliferation	246

8.4.	Outcomes and Complications of Vitrectomy in Diabetic Retinopathy	246
8.4.1.	Outcomes	246
8.4.2.	Complications	247
8.4.2.1.	Recurrent vitreous hemorrhage	247
8.4.2.2.	Retinal breaks	248
8.4.2.3.	Retinal detachment	248
8.4.2.4.	Iris rubeosis and neovascular glaucoma	248
8.4.2.5.	Corneal epithelial complications	249
8.4.2.6.	Fibrin formation	249
8.5.	New Instrumentation	249
8.6.	Conclusions	251
	References	251
Chapter 9	Medical Management of Diabetic Retinopathy	257
	<i>José Rui Faria Abreu and José Cunha-Vaz</i>	
9.1.	Glycemic Control	257
9.1.1.	Glycemic Control and Diabetic Retinopathy	258
9.1.1.1.	Type 1 diabetes	258
9.1.1.2.	Type 2 Diabetes	259
9.2.	Blood Pressure Control	259
9.2.1.	Type 1 Diabetes	259
9.2.2.	Type 2 Diabetes	260
9.3.	Dyslipidemic Control	260
9.4.	Treatment of Anemia	261
9.5.	Experimental Therapies	262
9.5.1.	Modulation of Antithrombotic Function of the Endothelium: Platelet Function Inhibitors	262
9.5.2.	Angiotensin-Converting Enzyme Inhibitors	263
9.5.3.	Inhibitors of the Inducible Form of Nitric Oxide Synthase	263
9.5.4.	Antioxidants	264
9.5.5.	Inhibitors of Protein Kinase C (PKC)	265
9.5.6.	Inhibition of Nonenzymatic Glycation of Proteins and Advanced Glycation End Products	265
9.5.6.1.	Aminoguanidine	266
9.5.6.2.	Amadorins	266
9.5.6.3.	Pyridoxal phosphate	266
9.5.7.	Aldose Reductase Inhibitors	266
9.5.8.	Rheological Agents	267
9.5.9.	Antiinflammatory Agents	267
9.5.10.	Angiogenesis Signaling Inhibitors	268
9.5.10.1.	VEGF	269
9.5.10.2.	Pigment-epithelium derived factor	269
9.5.10.3.	Growth hormone	270

9.6.	Conclusions	270
	References	270
Chapter 10	An Integrated Perspective on Diabetic Retinopathy in Type 2 Diabetes <i>José Cunha-Vaz</i>	279
10.1.	Limitations of Present Classifications of Nonproliferative Diabetic Retinopathy	280
10.2.	Natural History of the Initial Stages of NPDR	281
10.3.	Markers of Diabetic Retinal Disease	283
10.3.1.	Microaneurysms/Hemorrhages. Red-dots Formation and Disappearance Rates	283
10.3.2.	Alteration of the BRB. Fluorescein Leakage Measurements	286
10.3.3.	Macular Edema. Retinal Thickness Measurements	289
10.3.4.	Retinal Blood Flow and Capillary Closure	292
10.3.5.	Neuronal and Glial Cells Changes	294
10.3.6.	Multimodal Imaging of the Retina	295
10.4.	Characterization of Retinopathy Phenotypes	296
10.4.1.	Follow-up Studies of the Initial Stages of Diabetic Retinopathy by Multimodal Retinal Imaging	296
10.4.2.	Progression of Nonproliferative Retinopathy Under Stabilized Metabolic Control	300
10.5.	Dominant Pathophysiological Mechanisms of Disease Progression	301
10.5.1.	Aging Phenomena	301
10.5.2.	Hemodynamic Phenomena	302
10.5.3.	Thrombotic Phenomena	303
10.5.4.	Adjuvant Phenomena	304
10.6.	Biochemical Pathways Involved	304
10.7.	Candidate Phenotype/Genotype Correlations	305
10.8.	Relevance for Clinical Trial Design	308
10.9.	Relevance for Clinical Management	309
10.10.	Targeted Treatments	310
10.11.	Determining Risk in the Individual Patient. Preventative Ophthalmology	311
	References	313
	<i>Index</i>	319

This page is intentionally left blank

List of Contributors

José Rui Faria de Abreu

Assistant Professor of Ophthalmology and Consultant Ophthalmologist
Ophthalmology Department, University Hospital of Coimbra
Coimbra, Portugal

Alda Ambrósio

Senior Researcher
Clinical and Molecular Genetics Unit
National Institute of Legal Medicine
Institute of Biomedical Research in Light and Image (IBILI)
Faculty of Medicine of the University of Coimbra
Coimbra, Portugal

António Francisco Ambrósio

Senior Researcher
Division of Retinal Dysfunction
Centre of Ophthalmology and Vision Sciences of the University of Coimbra
Institute of Biomedical Research in Light and Image (IBILI)
Faculty of Medicine of the University of Coimbra
Coimbra, Portugal

Rui Bernardes

Director
Centre of New Technologies for Medicine
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Assistant Professor of Biophysics/Biomathematics
Faculty of Medicine of University of Coimbra
Coimbra, Portugal

Miguel Castelo Branco

Assistant Professor of Biophysics
Institute of Biophysics and Biomathematics
Visual Neuroscience Laboratory
Faculty of Medicine of the University of Coimbra
Director
Institute of Biomedical Research in Light and Image (IBILI)
Faculty of Medicine of the University of Coimbra
Coimbra, Portugal

José Cunha-Vaz

Emeritus Professor of Ophthalmology
University of Coimbra
President
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Coimbra, Portugal

Lilianne Duarte

Consultant Ophthalmologist
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Coimbra, Portugal

João Figueira

Consultant Ophthalmologist
Department of Ophthalmology, University Hospital of Coimbra
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Coimbra, Portugal

Francisco Gomez-Ulla

Professor of Ophthalmology
University Hospital of Santiago
Unit of Medical Retina and Ocular Diabetes
University of Santiago de Compostela
Technological Institute of Ophthalmology
Santiago Compostela, Spain
Ophthalmology Hospital of Santa Teresa
La Coruna, Spain

José Carlos Pastor Jimeno

Professor of Ophthalmology
University of Valladolid
Director of Instituto Universitario de Oftalmología Aplicada (IOBA)
Chief of Department of the University Hospital
Valladolid, Spain

Ermelindo Leal

Researcher

Centre of Ophthalmology and Vision Sciences of the University of Coimbra

Institute of Biomedical Research in Light and Image (IBILI)

Faculty of Medicine of the University of Coimbra

Coimbra, Portugal

Conceição Lobo

Assistant Professor of Ophthalmology and Consultant Ophthalmologist

Faculty of Medicine of University of Coimbra and Department of Ophthalmology

University Hospital of Coimbra

Association for Innovation and Biomedical Research on Light and Image (AIBILI)

Coimbra, Portugal

Paulo Pereira

Director

Centre of Ophthalmology and Vision Sciences of the University of Coimbra

Institute of Biomedical Research in Light and Image (IBILI)

Faculty of Medicine, University of Coimbra

Vice-Director

Faculty of Medicine, University of Coimbra

Coimbra, Portugal

Luisa Ribeiro

Director and Consultant Ophthalmologist

Clinical Trial Centre, Association for Innovation and Biomedical Research on Light and Image (AIBILI)

Coimbra, Portugal